Phenylketonuria

Synlogic publishes papers in Nature journals demonstrating proof-of-mechanism and potential of synth

SYNB1618 demonstrates dose-responsive, non-saturated increases in gastrointestinal Phe consumption, suggesting therapeutic potential for Phenylketonuria (PKU). A mechanistic model predicts SYNB1618's function in PKU patients and informs clinical development.

DJI Air 3 (RC-N2)

DJI Air 3 (RC-N2) captures 4K mapping passes and environmental surveys with dual cameras, long flight time, and omnidirectional obstacle sensing.

Russian scientists improved the way of treatment of phenylketonuria

Researchers develop stable capsule shell for L-phenylalanine ammonium-liasis (PAL) enzyme, improving its effectiveness and stability in the body. The treatment has potential applications beyond phenylketonuria, including other amino acid metabolism disorders.

IKBFU scientists developed capsule composition for enzyme against intellectual disability

Researchers at IKBFU developed a stable capsule composition for the L-phenylalanine-ammonium lyase enzyme to treat phenylketonuria. The study found that storage temperatures above 25°C significantly decrease enzyme activity, but the optimal temperature remains unknown.

Bringing stability to the protein defective in phenylketonuria

Researchers identified four small molecules that stabilize both normal and mutated PAH proteins, increasing their activity and amount in human cells. These findings suggest chaperones might provide a new approach to treating individuals with phenylketonuria.

Unique whey protein is promising supplement for strict PKU diet

Researchers at University of Wisconsin-Madison discover a unique protein in whey that supports growth and reduces phenylalanine levels in mice with PKU, opening possibilities for dietary liberalization.